Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP536232.RACyHztSSUFJ1rbGXOKiVA-5t7G6vQf6MW-05HXX8QsNQ130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP536232.RACyHztSSUFJ1rbGXOKiVA-5t7G6vQf6MW-05HXX8QsNQ130_assertion type Assertion NP536232.RACyHztSSUFJ1rbGXOKiVA-5t7G6vQf6MW-05HXX8QsNQ130_head.
- NP536232.RACyHztSSUFJ1rbGXOKiVA-5t7G6vQf6MW-05HXX8QsNQ130_assertion description "[Recently, we examined the role of PPARgamma in EAE and observed that administration of the PPARgamma agonist 15-deoxy-Delta(12,14) prostaglandin J2 exerted a significant therapeutic effect predominantly by inhibiting the activation and expansion of encephalitogenic T cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP536232.RACyHztSSUFJ1rbGXOKiVA-5t7G6vQf6MW-05HXX8QsNQ130_provenance.
- NP536232.RACyHztSSUFJ1rbGXOKiVA-5t7G6vQf6MW-05HXX8QsNQ130_assertion evidence source_evidence_literature NP536232.RACyHztSSUFJ1rbGXOKiVA-5t7G6vQf6MW-05HXX8QsNQ130_provenance.
- NP536232.RACyHztSSUFJ1rbGXOKiVA-5t7G6vQf6MW-05HXX8QsNQ130_assertion SIO_000772 16484546 NP536232.RACyHztSSUFJ1rbGXOKiVA-5t7G6vQf6MW-05HXX8QsNQ130_provenance.
- NP536232.RACyHztSSUFJ1rbGXOKiVA-5t7G6vQf6MW-05HXX8QsNQ130_assertion wasDerivedFrom befree-2016 NP536232.RACyHztSSUFJ1rbGXOKiVA-5t7G6vQf6MW-05HXX8QsNQ130_provenance.
- NP536232.RACyHztSSUFJ1rbGXOKiVA-5t7G6vQf6MW-05HXX8QsNQ130_assertion wasGeneratedBy ECO_0000203 NP536232.RACyHztSSUFJ1rbGXOKiVA-5t7G6vQf6MW-05HXX8QsNQ130_provenance.